Mongoose Bio Inc.

Mongoose Bio, Inc. is an innovative clinical-stage biopharmaceutical company at the forefront of precision oncology, pioneering first-in-class T cell receptor T cell (TCR-T) therapies. By leveraging our proprietary antigen discovery pipeline and advanced memory T cell reprogramming technology, we achieve unparalleled coverage of both common and rare solid tumors, delivering sustained immunoprotection. We integrate Generative Artificial Intelligence (Gen AI) to enhance our antigen discovery and T cell engineering processes, optimizing therapeutic efficacy and patient outcomes. The science and extensive intellectual property behind Mongoose Bio were developed by Dr. Cassian Yee, a leading oncologist at the prestigious MD Anderson Cancer Center in Houston, Texas. Mongoose Bio holds an exclusive license from MD Anderson to develop and commercialize the TCR-T technology worldwide. Mongoose Bio’s mission is to generate active and persistent TCR-T therapeutics by epigenetic reprogramming of autologous central memory T-cells harboring defined TCR’s against empirically validated highly immunogenic tumor targets.